Stay up-to-date on our latest news.
Jan 28, 2020
Clover Initiates Development of Recombinant Subunit-Trimer Vaccine for Coronavirus (2019-nCoV)Jan 10, 2020
Clover Doses First Patient in Phase I Study of SCB-313 in China for Malignant Pleural Effusions (MPE)Dec 30, 2019
Clover Initiates Phase III Study of Etanercept Biosimilar Candidate SCB-808 in ChinaNov 28, 2019
Clover Completes $43 Million Series B FinancingNov 21, 2019
Clover Doses First Patient in Phase I Study of SCB-313 in Australia for Malignant Pleural Effusions (MPE)Sep 29, 2019
Clover Doses First Patient in Phase I Study of SCB-313 in China for Malignant AscitesSep 10, 2019
Clover Doses First Patient in Phase I Study of SCB-313 in China for Peritoneal CarcinomatosisMay 07, 2019
Clover Receives NMPA Approval for SCB-313 (TRAIL-Trimer) to Initiate Clinical Trials in ChinaAug 01, 2018
Clover Initiates Phase I Study of Etanercept Biosimilar Candidate SCB-808 in ChinaJun 18, 2018
Clover Doses First Patient in Australia in Phase I Study of SCB-313 for Malignant Ascites